智通财经APP讯，山东新华制药股份(00719)发布公告，近日，公司收到国家药品监督管理局核准签发的恩他卡朋片(以下简称“本品”)《药品注册证书》。
本品可作为标准药物左旋多巴/苄丝肼或左旋多巴/卡比多巴的辅助用药，用于治疗以上药物不能控制的帕金森病及剂末现象(症状波动)
本品属于《国家基本医疗保险、工伤保险和生育保险药品目录(2025年)》乙类品种。根据相关统计数据，2024年中国公立医疗机构恩他卡朋片销售额约为人民币2.86亿元。
新华制药申报的恩他卡朋片于近期获得药品注册证书，进一步丰富了公司的制剂产品系列，有利于提升公司综合竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.